Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Atypical antipsychotics (AAPs) are increasingly used for the treatment of psychotic disorders but are known to be associated with metabolic abnormalities. This study is a systematic review and meta-analysis of randomized controlled trials (RCTs) studying the effectiveness of melatonin for the amelioration of AAP-induced metabolic syndrome. The MEDLINE (accessed via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials, PsycINFO, LILACS, CINAHL, and OpenGrey databases were searched for RCTs without language restrictions. Inclusion criteria were randomized, double-blind clinical trials comparing melatonin or melatonin agonists with placebo for the amelioration of AAP-induced effects at any age with selected components of metabolic syndrome as outcome measures. Two reviewers independently selected articles and assessed quality using Cochrane risk of bias and concealment tools. Of 53 records, five RCTs were eligible for the systematic review and three for the meta-analysis. The meta-analyses showed no statistically significant difference in any anthropometric or metabolic variable considered. Analysis according to psychiatric diagnosis from one RCT showed significant decreases in diastolic blood pressure (5.5 vs. −5.7 mmHg for the placebo and melatonin groups, respectively; p =0.001), fat mass (2.7 vs. 0.2 kg, respectively; p =0.032), and triglycerides (D) (50.1 vs. −20 mg/dl, respectively; p =0.08) in the bipolar group but not the schizophrenia group. Although limited to five RCTs with small sample sizes, evidence from RCT indicates that melatonin improves AAP-induced metabolic syndrome. This beneficial effect seems more significant in patients with bipolar disorder than those with schizophrenia. Further RCTs are needed to definitively establish the potential ameliorative effect of melatonin and to justify its efficacy as an add-on therapy to curtail AAP-induced metabolic syndrome.
Abstract
Atypical antipsychotics (AAPs) are increasingly used for the treatment of psychotic disorders but are known to be associated with metabolic abnormalities. This study is a systematic review and meta-analysis of randomized controlled trials (RCTs) studying the effectiveness of melatonin for the amelioration of AAP-induced metabolic syndrome. The MEDLINE (accessed via PubMed), Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials, PsycINFO, LILACS, CINAHL, and OpenGrey databases were searched for RCTs without language restrictions. Inclusion criteria were randomized, double-blind clinical trials comparing melatonin or melatonin agonists with placebo for the amelioration of AAP-induced effects at any age with selected components of metabolic syndrome as outcome measures. Two reviewers independently selected articles and assessed quality using Cochrane risk of bias and concealment tools. Of 53 records, five RCTs were eligible for the systematic review and three for the meta-analysis. The meta-analyses showed no statistically significant difference in any anthropometric or metabolic variable considered. Analysis according to psychiatric diagnosis from one RCT showed significant decreases in diastolic blood pressure (5.5 vs. −5.7 mmHg for the placebo and melatonin groups, respectively; p =0.001), fat mass (2.7 vs. 0.2 kg, respectively; p =0.032), and triglycerides (D) (50.1 vs. −20 mg/dl, respectively; p =0.08) in the bipolar group but not the schizophrenia group. Although limited to five RCTs with small sample sizes, evidence from RCT indicates that melatonin improves AAP-induced metabolic syndrome. This beneficial effect seems more significant in patients with bipolar disorder than those with schizophrenia. Further RCTs are needed to definitively establish the potential ameliorative effect of melatonin and to justify its efficacy as an add-on therapy to curtail AAP-induced metabolic syndrome.
참고문헌 (29)
- Leo RJ, "Atypical antipsychotic use in the treatment of psychosis in primary care", Prim Care Companion J Clin Psychiatry, 2, pp.194~204 (2000)[DOI]
- Calarge CA, "Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents", J Child Adolesc Psychopharmacol, 19, pp.101~109 (2009)[DOI]
- 고유경, "The Prevalence of Metabolic Syndrome in Schizophrenic Patients Using Antipsychotics", Clinical Psychopharmacology and Neuroscience, 11(2), pp.80~88 (2013), 대한정신약물학회
- Deedwania PC, "Management issues in the metabolic syndrome", J Assoc Physicians India, 54, pp.797~810 (2006)
- Fontaine KR, "Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate", Psychiatry Res, 101, pp.277~288 (2001)[DOI]
- Srinivasan V, "Metabolic syndrome, its pathophysiology and the role of melatonin", Recent Pat Endocr Metab Immune Drug Discov, 7, pp.11~25 (2013)[DOI]
- Grundy SM, "Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute", American Heart Association conference on scientific issues related to definition, 2004, pp.109, 433~438
- Daniels SR, "Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment", Circulation, 111, pp.1999~2012 (2005)[DOI]
- Gavin P. Reynolds, "Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review", Clinical Psychopharmacology and Neuroscience, 10(2), pp.71~77 (2012), 대한정신약물학회[DOI]
- Kroeze WK, "H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs", Neuropsychopharmacology, 28, pp.519~526 (2003)[DOI]
- Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)[DOI]
- Baptista T, "Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives", Pharmacopsychiatry, 35, pp.205~219 (2002)[DOI]
- Modabbernia A, "Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study", J Psychiatr Res, 53, pp.133~140 (2014)[DOI]
- Pevet P, "Melatonin: both master clock output and internal time-giver in the circadian clocks network", J Physiol Paris, 105, pp.170~182 (2011)[DOI]
- Raskind MA, "Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats", Neuropsychopharmacology, 32, pp.284~288 (2007)[DOI]
- Espino J, "Role of melatonin on diabetes-related metabolic disorders", World J Diabetes, 2, pp.82~91 (2011)[DOI]
- Moher D, "Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement", PLoS Med, 6, pp.e1000097~ (2009)[DOI]
- Higgins JPT, "Cochrane handbook for systematic reviews of interventions, version 5.1.0" (2011), Cochrane Collaboration
- Higgins JP, "Measuring inconsistency in meta-analyses", BMJ, 327, pp.557~560 (2003)[DOI]
- Borba CP, "Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia", J Clin Psychopharmacol, 31, pp.653~658 (2011)
- Mostafavi A, "Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial", Acta Med Iran, 52, pp.734~739 (2014)
- Romo-Nava F, "Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial", Bipolar Disord, 16, pp.410~421 (2014)[DOI]
- Mostafavi SA, "Melatonin for reducing weight gain following administration of atypical antipsychotic olanzapine for adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled trial", J Child Adolesc Psychopharmacol, 27, pp.440~444 (2017)[DOI]
- Wang HR, "The role of melatonin and melatonin agonists in counteracting antipsychotic-induced metabolic side effects: a systematic review", Int Clin Psychopharmacol, 31, pp.301~306 (2016)[DOI]
- Hildrum B, "Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study", BMC Public Health, 7, pp.220~ (2007)[DOI]
- Teixeira PJ, "The prevalence of metabolic syndrome among psychiatric inpatients in Brazil", Rev Bras Psiquiatr, 29, pp.330~336 (2007)[DOI]
- Genc A, "The prevalence of metabolic syndrome parameters among bipolar disorder outpatients on lithium monotherapy", Klinik Psikofarmakol Bulteni, 22, pp.320~324 (2012)[DOI]
- Vancampfort D, "Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators", Am J Psychiatry, 170, pp.265~274 (2013)[DOI]
- Wulff K, "Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease", Nat Rev Neurosci, 11, pp.589~599 (2010)